New gene variant identified for advance PCa. From the Cleveland Clinic Press Release:
"This study – the first clinical trial validation of the relationship between HSD3B1 status and clinical outcomes – suggests that genetic testing for HSD3B1(1245C) may help physicians identify patients most likely to benefit from additional and more aggressive treatment . . .
Taken together, these findings suggest that the presence or absence of this genetic variant can be used to help identify men with low-volume metastatic prostate cancer most at risk for quick progression to treatment resistance and earlier death – a discovery with significant implications for clinical care and genetic counseling."
The Science continues to develop as they look at genetic variability and survivability and approaches to treatment. It is why I believe we will hit chronic disease status within a few years and the 5 year survival rate will change dramatically...Another genetic variant to be aware of at the start of treatment...
The podcast was great cujoe. Thank you. Easy to understand and informative. This article from UroToday taken from ASCO 2019 touches on some of the information gleaned from the trials.
Thanks, Marnie. UroToday piece is a good review of the CC research. I now see that the JAMAnetwork link puts the full report behind a paywall. Insert this doi (doi:10.1001/jamaoncol.2019.6496) into this SciHub link to get a PDF download of the full report.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Albumin